文献速递肝病

NLRP3炎症小体阻断减轻实验性NASH小鼠的肝脏炎症和纤维化

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
PubMed 文献 · J Hepatol · 2017-02-03

研究使用首个小分子NLRP3抑制剂MCC950,在两种小鼠脂肪性肝炎模型中测试炎症小体阻断对炎症招募和肝纤维化的影响。在foz/foz和野生型小鼠中,MCC950治疗使肝脏caspase 1和IL-1β表达正常化,降低血浆IL-1β、MCP-1和IL-6,降低ALT/AST,减轻NASH病理和肝纤维化。在MCD饮食小鼠中,MCC950抑制肝脏caspase 1和IL-1β升高,降低肝脏巨噬细胞和中性粒细胞数量,改善肝纤维化。

要点

  • MCC950阻断NLRP3炎症小体可减轻实验性NASH小鼠的肝脏炎症和纤维化。
  • 胆固醇结晶可激活Kupffer细胞和巨噬细胞释放IL-1β,MCC950可消除此作用及相关中性粒细胞迁移。
  • 靶向NLRP3是NASH药物治疗的一个合理方向。

核心结论

  • NLRP3选择性抑制剂MCC950改善了肥胖糖尿病小鼠的NAFLD病理和纤维化,可能归因于阻断了髓系细胞中胆固醇结晶介导的NLRP3激活。
  • MCC950减轻了MCD喂养小鼠的肝纤维化。
  • 靶向NLRP3是NASH药物治疗的一个合理方向。

研究设计与样本

  • 在两种小鼠脂肪性肝炎模型中测试MCC950:foz/foz和野生型小鼠喂食致动脉粥样硬化饮食16周,然后灌胃MCC950或溶媒至24周,确定NAFLD表型。
  • 在喂食蛋氨酸/胆碱缺乏(MCD)饮食的小鼠中,灌胃MCC950或溶媒6周,确定对肝纤维化的影响。

主要发现

  • 在溶媒处理的foz/foz小鼠中,24周时肝脏NLRP3、pro-IL-1β、活性caspase-1和IL-1β表达增加,伴有胆固醇结晶形成和NASH病理;血浆IL-1β、IL-6、MCP-1、ALT/AST均升高。
  • MCC950治疗使肝脏caspase 1和IL-1β表达、血浆IL-1β、MCP-1和IL-6正常化,降低ALT/AST,并减轻肝脏炎症严重程度(包括NASH病理指定)和肝纤维化。
  • 体外实验中,胆固醇结晶激活Kupffer细胞和巨噬细胞释放IL-1β;MCC950消除了这一作用及相关的中性粒细胞迁移。
  • MCD饮食喂养的小鼠发生纤维化性脂肪性肝炎;MCC950抑制肝脏caspase 1和IL-1β的升高,降低肝脏中巨噬细胞和中性粒细胞数量,并改善肝纤维化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alcoholic fatty liver disease (NAFLD). We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis. METHODS: We fed foz/foz and wild-type mice an atherogenic diet for 16weeks, gavaged MCC950 or vehicle until 24weeks, then determined NAFLD phenotype. In mice fed an methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle for 6weeks and determined the effects on liver fibrosis. RESULTS: In vehicle-treated foz/foz mice, hepatic expression of NLRP3, pro-IL-1β, active caspase-1 and IL-1β increased at 24weeks, in association with cholesterol crystal formation and NASH pathology; plasma IL-1β, IL-6, MCP-1, ALT/AST all increased. MCC950 treatment normalized hepatic caspase 1 and IL-1β expression, plasma IL-1β, MCP-1 and IL-6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as NASH pathology, and liver fibrosis. In vitro, cholesterol crystals activated Kupffer cells and macrophages to release IL-1β; MCC950 abolished this, and the associated neutrophil migration. MCD diet-fed mice developed fibrotic steatohepatitis; MCC950 suppressed the increase in hepatic caspase 1 and IL-1β, lowered numbers of macrophages and neutrophils in the liver, and improved liver fibrosis. CONCLUSION: MCC950, an NLRP3 selective inhibitor, improved NAFLD pathology and fibrosis in obese diabetic mice. This is potentially attributable to the blockade of cholesterol crystal-mediated NLRP3 activation in myeloid cells. MCC950 reduced liver fibrosis in MCD-fed mice. Targeting NLRP3 is a logical direction in pharmacotherapy of NASH. LAY SUMMARY: Fatty liver disease caused by being overweight with diabetes and a high risk of heart attack, termed non-alcoholic steatohepatitis (NASH), is the most common serious liver disease with no current treatment. There could be several causes of inflammation in NASH, but activation of a protein scaffold within cells termed the inflammasome (NLRP3) has been suggested to play a role. Here we show that cholesterol crystals could be one pathway to activate the inflammasome in NASH. We used a drug called MCC950, which has already been shown to block NLRP3 activation, in an attempt to reduce liver injury in NASH. This drug partly reversed liver inflammation, particularly in obese diabetic mice that most closely resembles the human context of NASH. In addition, such dampening of liver inflammation in NASH achieved with MCC950 partly reversed liver scarring, the process that links NASH to the development of cirrhosis.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Mridha AR, Wree A, Robertson AAB, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017. PMID: 28167322. doi:10.1016/j.jhep.2017.01.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。